Global Bioresorbable Polymers Market Size By Type (Polylactic Acid (PLA), Polyglycolic Acid (PGA), Poly(lactic-co-glycolic acid) (PLGA), Polycaprolactone (PCL)), By Application (Orthopedic Devices, Drug Delivery), By Geographic Scope And Forecast

Bioresorbable Polymers Market Size And Forecast

Bioresorbable Polymers Market size was valued at USD 22.15 Billion in 2024 and is projected to reach USD 60.58 Billion by 2032, growing at a CAGR of 13.40% from 2026 to 2032.

Bioresorbable polymers are intrinsically biocompatible and hydrolytically unstable, making them suitable for use in temporary implants that will be absorbed and metabolized by the human body.

These polymers are widely employed in applications such as orthopedic fixing, vascular stents, tissue engineering, and controlled drug delivery.

Global Bioresorbable Polymers Market Dynamics

The key market dynamics that are shaping the bioresorbable polymers market include:

Key Market Drivers

Increasing Air Passenger Traffic: The rising prevalence of cardiovascular illnesses is pushing up demand for bioresorbable stents constructed from bioresorbable polymers. According to the World Health Organization (WHO), cardiovascular disease is the leading cause of death worldwide, killing an estimated 17.9 million people each year. This increasing prevalence encourages the use of bioresorbable stents, which drives the bioresorbable polymers market.

Stringent Safety Regulations: The expanding number of orthopedic procedures, notably fracture fixation and tissue engineering, is driving up demand for bioresorbable polymers. According to the American Academy of Orthopedic Surgeons, around 6.8 million orthopedic surgeries are performed in the United States alone each year. This high volume of treatments encourages the use of bioresorbable polymers in implants and fixation devices.

Technological Advancements in Oxygen Generation Systems: The pharmaceutical industry's emphasis on creating new drug delivery technologies is driving the bioresorbable polymer market. According to a survey from the Pharmaceutical Research and Manufacturers of America (PhRMA), the biopharmaceutical industry invested an estimated $102 billion in R&D in 2022. A large percentage of this investment is going into developing novel drug delivery systems, many of which use bioresorbable polymers.

Key Challenges:

Higher Costs: Bioresorbable polymers are substantially more expensive than typical medical polymers, sometimes exceeding $2,200 per kilogram. Higher production costs are a serious constraint, particularly for applications requiring cost-effectiveness or in price-sensitive markets.

Competition from Non-Resorbable Polymers: In some applications, non-resorbable polymers may be selected due to their established performance or cheaper cost. The rivalry from established non-bioresorbable materials limits the bioresorbable polymers market's growth potential.

Key Trends:

Increase in Adoption in Tissue Engineering: The bioresorbable polymers market is expanding rapidly in tissue engineering applications, owing to advances in scaffold design and cell culture techniques. This trend is predicted to continue as bioresorbable polymers help with tissue regeneration and enhance patient outcomes in regenerative medicine.

Integration with Advanced Drug Delivery Systems: The introduction of improved drug delivery systems into bioresorbable polymers is an important trend. This allows for more accurate and controlled therapeutic release, which improves therapy efficacy and patient outcomes in a variety of medicinal applications. This merger is likely to accelerate market growth.

Growing Use in Sustainable Packaging: The demand for environmentally responsible packaging solutions is growing, and bioresorbable polymers offer long-term options. This trend is projected to continue as the market grows to encompass packaging applications for bioresorbable polymers, which are biodegradable and compostable.

Global Bioresorbable Polymers Market Regional Analysis

Here is a more detailed regional analysis of the bioresorbable polymers market:

North America:

According to Verified Market Research, North America is estimated to dominate the bioresorbable polymers market during the forecast period. North America has a high incidence of cardiovascular illness, which is increasing demand for bioresorbable stents and other bioresorbable polymer-based medical devices. According to the American Heart Association's 2023 Heart Disease and Stroke Statistics, approximately 126.9 million adults in the United States have some type of cardiovascular disease. This high incidence is driving the development of innovative medical devices, particularly those that use bioresorbable polymers.

The North American region has a high number of orthopedic procedures, which increases the demand for bioresorbable polymers used in implants and fixation devices. According to the American Academy of Orthopedic Surgeons, about 1 million joint replacements are performed annually in the United States. This large volume of treatments drives the bioresorbable polymers market in the region.

Furthermore, North America, especially the United States, is a leader in healthcare research and development, including the creation of new applications for bioresorbable polymers. According to the National Institutes of Health (NIH), the NIH's legislated budget for FY 2023 was $47.5 billion, with a major amount going toward research involving advanced materials such as bioresorbable polymers. This amount of investment stimulates innovation and market expansion in the bioresorbable polymers market.

Europe:

Europe region is estimated to exhibit the highest growth during the forecast period. Europe's population is aging, which increases the incidence of cardiovascular illnesses and drives up demand for bioresorbable stents. According to Eurostat, the proportion of adults 65 and older in the EU-27 is expected to rise from 20.3% in 2019 to 29.4% by 2050. The European Heart Network states that cardiovascular illnesses kill 3.9 million people in Europe each year, accounting for 45% of all deaths. The demographic shift and illness burden are driving the use of bioresorbable polymers in cardiovascular applications.

The region has an advanced healthcare system encourages the use of breakthrough medical technology, including bioresorbable polymers. The European Federation of National Associations of Orthopedics and Traumatology (EFORT) estimates that more than 7 million orthopedic treatments are performed in Europe each year. The large volume of surgeries, combined with the region's superior healthcare infrastructure, is driving increased demand for bioresorbable polymers in orthopedic applications.

Furthermore, Europe has a strong presence in pharmaceutical and medical device research, which drives innovation in bioresorbable polymers. According to the European Federation of Pharmaceutical Industries and Associations (EFPIA), the pharmaceutical sector invested roughly €39.0 billion in research and development in Europe in 2021. A large percentage of this research is focused on enhanced drug delivery systems and medical devices, many of which include bioresorbable polymers.

Asia Pacific:

The Asia Pacific region is estimated to exhibit substantial growth during the forecast period. The Asia Pacific region is experiencing a large increase in cardiovascular illness, which is increasing the demand for bioresorbable polymer stents. According to the World Health Organization (WHO), cardiovascular illnesses cause 35% of all fatalities in the Western Pacific Region, which covers much of Asia. In China alone, nearly 290 million individuals suffer from cardiovascular disease. This high illness load is driving the introduction of sophisticated medical devices made from bioresorbable polymers.

The increasing number of orthopedic procedures in the Asia Pacific region is driving up demand for bioresorbable polymers used in implants and fixation devices. According to a study published in The Lancet, the number of hip and knee replacement surgeries in Asia is anticipated to rise by 174% from 2015 to 2030. In China, the number of these treatments is expected to reach 1.3 million by 2030. The increase in orthopedic surgeries is propelling the bioresorbable polymers market in the region.

Furthermore, the rapid growth of the pharmaceutical and biotechnology sectors in the Asia Pacific is driving research and development into bioresorbable polymer-based drug delivery systems. According to the India Brand Equity Foundation, the Indian pharmaceutical sector is predicted to grow to $65 billion by 2024. Similarly, the International Trade Administration projects that China's pharmaceutical industry reached $161.8 billion by 2023. This expansion is fueling innovation in medication delivery systems, many of which include bioresorbable polymers.

Global Bioresorbable Polymers Market: Segmentation Analysis

The Global Bioresorbable Polymers Market is segmented based on Type, Application, and Geography.

Bioresorbable Polymers Market, By Type

• Polylactic acid (PLA)
• Polyglycolic acid (PGA)
• Poly(lactic-co-glycolic) acid (PLGA)
• Polycaprolactone (PCL)
• Others

Based on Type, the market is segmented into Polylactic acid (PLA), Polyglycolic acid (PGA), Poly(lactic-co-glycolic) acid (PLGA), Polycaprolactone (PCL), and Others. The polylactic acid (PLA) segment is estimated to dominate the bioresorbable polymers market. PLA is a biodegradable and biocompatible polymer that finds widespread use in medical applications such as sutures, implants, and drug delivery systems. Its high processability, mechanical strength, and biodegradability make it an ideal material for a variety of medical devices and implants.

Bioresorbable Polymers Market, By Application

• Orthopedic Devices
• Drug Delivery
• Others

Based on Application, the market is segmented into Orthopedic Devices, Drug Delivery, and Others. The orthopedic device segment is estimated to dominate the bioresorbable polymers market during the forecast period. The increasing prevalence of orthopedic illnesses, the need for biocompatible medical devices, the number of surgical treatments, and a tendency toward minimally invasive orthopedic procedures all contribute to the rapid expansion of the orthopedics segment. Bioresorbable polymers are especially beneficial in orthopedics because they can give temporary support during the healing process without necessitating further implant removal procedures. This eliminates the difficulties associated with non-resorbable implants.

Bioresorbable Polymers Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

Based on Geography, the Bioresorbable Polymers market is classified into North America, Europe, Asia Pacific, and the Rest of the World. North America is estimated to dominate the bioresorbable polymers market during the forecasted period due to a high degree of technological expertise in the healthcare industry, particularly in the United States and Canada, as well as high healthcare spending, a significant presence of medical device makers, and the region's increasing frequency of orthopedic illnesses.

Key Players

• The "Bioresorbable Polymers Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Corbion N.V., Evonik Industries AG, BASF SE, NatureWorks LLC, Eastman Chemical Company, Total Corbion PLA, Novamont S.p.A., Ashland Global Holdings, Inc., Arkema SA, and Boonton, Inc.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• Bioresorbable Polymers Market Recent Developments
• In March 2021, Ashland Global Holdings Inc. extended its Viatel bioresorbable polymer production line and transferred R&D from Dublin to Mullingar's National Science Park.